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Structural and molecular basis of ZNRF3/RNF43
transmembrane ubiquitin ligase inhibition
by the Wnt agonist R-spondin
Matthias Zebisch1, Yang Xu2,3, Christos Krastev1, Bryan T. MacDonald2, Maorong Chen2,
Robert J.C. Gilbert1, Xi He2 & E. Yvonne Jones1
The four R-spondin (Rspo) proteins are secreted agonists of Wnt signalling in vertebrates,
functioning in embryogenesis and adult stem cell biology. Through ubiquitination and
degradation of Wnt receptors, the transmembrane E3 ubiquitin ligase ZNRF3 and related
RNF43 antagonize Wnt signalling. Rspo ligands have been reported to inhibit the ligase
activity through direct interaction with ZNRF3 and RNF43. Here we report multiple crystal
structures of the ZNRF3 ectodomain (ZNRF3ecto), a signalling-competent Furin1–Furin2
(Fu1–Fu2) fragment of Rspo2 (Rspo2Fu1–Fu2), and Rspo2Fu1–Fu2 in complex with ZNRF3ecto, or
RNF43ecto. A prominent loop in Fu1 clamps into equivalent grooves in the ZNRF3ecto and
RNF43ecto surface. Rspo binding enhances dimerization of ZNRF3ecto but not of RNF43ecto.
Comparison of the four Rspo proteins, mutants and chimeras in biophysical and cellular
assays shows that their signalling potency depends on their ability to recruit ZNRF3 or RNF43
via Fu1 into a complex with LGR receptors, which interact with Rspo via Fu2.
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R
spo (R-spondin, also roof plate-speciﬁc spondin) proteins
are evolutionarily conserved from ﬁsh to humans and have
well-documented roles in a broad range of developmental
and physiological processes resulting from enhancement of
canonical and non-canonical Wnt signalling1–3. Rspo1 is
involved in mammalian sex determination4 and is a potent
stimulator of epithelial repair in the gastrointestinal tract2,5.
Rspo2 has recently been identiﬁed as a major determinant of
susceptibility to infectious diarrhoea in mice, linking infection
and intestinal homoeostasis6. Gene fusions involving RSPO2 and
RSPO3 have been found in 10% of primary colon cancers7,
whereas mutations in RSPO4 underlie inherited anonychia, a
disorder in nail development8–10. The leucine-rich repeat
containing G protein-coupled receptors 4, 5 and 6 (LGR4/5/6)
are conserved high-afﬁnity cell surface receptors for Rspo
proteins11–15; however, the molecular mechanisms by which
Rspo proteins function have remained obscure.
Recently published work has indicated that Rspo proteins can
exert their potentiating effects on Wnt signalling through direct
interaction with the extracellular regions of ZNRF3 or RNF43,
ultimately inducing formation of a complex comprising ZNRF3/
RNF43, Rspo and LGR4/5/6 (ref. 16). Similar to the Rspo proteins,
ZNRF3 and RNF43 are highly conserved in vertebrates. Loss-of-
function mutations of RNF43 in pancreatic cancer have implicated
it as a tumour suppressor17. ZNRF3 and RNF43 comprise an
amino-terminal extracellular region of uncharacterized topology
and moderate sequence conservation of 39% identity between the
two proteins, a transmembrane region and a cytoplasmic region
that bears the hallmark sequence of a really interesting new gene
(RING)-type E3 ubiquitin ligase. Similar to LGR4/5/6 receptors,
ZNRF3/RNF43 have been reported to associate in the membrane
with the Wnt receptor Frizzled and LRP5/6 coreceptors13,16.
ZNRF3/RNF43 speciﬁcally targets these Wnt receptors for
ubiquitination and turnover, hence reducing Wnt signalling
responses16,18. Direct extracellular interaction with Rspo
proteins inhibits ZNRF3/RNF43 activity16. These observations
have led to the suggestion that Rspo acts to physically bridge
between its two receptor types ZNRF3/RNF43 and LGR4/5/6 (ref.
16). Current models suggest that membrane clearance of ZNRF3/
RNF43 through this ternary complex relieves turnover of Wnt
receptors and hence enhances Wnt responsiveness.
Here we report a molecular level analysis of the ZNRF3/RNF43
ectodomain structure and its interactions with Rspo proteins. Our
study provides mechanistic insight into this key control point in
the Wnt signalling pathway.
Results
Structure determination. Sequence analyses suggest a putative
domain structure for the Rspo proteins comprising two furin-like
cysteine-rich regions (Fu domains) plus a thrombospondin type 1
repeat domain3 (Fig. 1a). Our own and published data point to the
involvement of the Fu domains in the potentiation of canonical
Wnt signalling by Rspo proteins1,19–21 (Supplementary Fig. S1).
We therefore engineered constructs to express the region spanning
the two Fu domains of Rspo2 proteins from several species. We
also generated secreted forms of the corresponding ZNRF3 and
RNF43 ectodomains. The Rspo2Fu1–Fu2 and respective ZNRF3ecto
or RNF43ecto molecules migrated together in gel ﬁltration
chromatography indicating high-afﬁnity binding (data not
shown), substantiating their ligand–receptor relationship. By
using a combination of heavy atom and molecular-replacement-
based phasing strategies, we determined multiple crystal structures
for Xenopus (x) Rspo2Fu1–Fu2 (highest resolution 2.2Å),
xZNRF3ecto, zebraﬁsh (z) ZNRF3ecto and mouse (m) ZNRF3ecto,
(highest resolutions 2.4, 1.6 and 2.0Å, respectively), plus
complexes comprising xZNRF3ecto–xRspo2Fu1–Fu2, mZNRF3ecto–
mRspo2Fu1–Fu2, mZNRF3ecto–xRspo2Fu1–Fu2 and xRNF4F3ecto–
xRspo2Fu1–Fu2 (at 2.1, 2.8, 2.4 and 2.7Å, respectively; see
Methods, Table 1 and Supplementary Table S1). In the
following sections and ﬁgures, the highest resolution structures
(Table 1 and Fig. 1) for the apo ligand, apo receptor and ligand–
receptor complex will be used unless otherwise stated.
Structure of the ZNRF3 ectodomain. The ZNRF3ecto crystal
structures revealed a distinctive variant of the protease-associated
domain topology22. Two b-sheets (comprising b2, b1, b7, b3
and b4, b5, b6 strands, respectively; Fig. 1b) splay apart,
accommodating an a-helix (aC) at the open edge; two additional
a-helices (aA and aB) pack against the b4, b5 and b6 face of this
distorted b-sandwich. A disulphide bridge, conserved across
species, links two structurally elaborate loops, b3–b4 and b4–aA.
The resultant single-domain structure is relatively compact. The
crystal structures for apo xZNRF3ecto, zZNRF3ecto and mZNRF3ecto
showed no major differences in the main chain conformation
(Supplementary Fig. S2). Comparisons of ZNRF3ecto structures for
proteins crystallized in several different crystal lattices, or for
crystals containing multiple copies in the asymmetric unit,
consistently highlighted an acidic region (N105-E114; residue
numbering is for mouse sequences unless otherwise stated) within
the b3–b4 loop, the short aC–b7 loop and the extended b1–b2
hairpin as ﬂexible elements of the fold (Supplementary Fig. S2). A
search of the Protein Data Bank for structures with a similar
topology yielded the ectodomain of GRAIL (gene related to anergy
in lymphocytes) as the closest match (deposited as an unpublished
crystal structure by J.R. Walker and colleagues, Structural
Genomics Consortium; Protein Data Bank ID code 3ICU).
GRAIL is a single-span transmembrane E3 ubiquitin ligase,
which localizes to the endosomal compartment and promotes
CD3 ubiquitinylation, acting as an essential regulator of T-cell
tolerance23,24. The sequence identity between ZNRF3 and GRAIL
ectodomains is low (13.4% for 127 residues); however, structural
superposition revealed a shared three-dimensional fold consistent
with a common evolutionary origin (r.m.s.d. 2.5Å for 131
equivalent Ca pairs; Supplementary Fig. S3a).
Our crystallographic data provided independent structures for
multiple copies of the ZNRF3 ectodomain in eight different
crystal forms (Table 1 and Supplementary Table S1). All but two
of these crystal structures reveal an extensive interface (average
interface area 992±109Å2; Supplementary Table S2) formed
between two ZNRF3ecto polypeptide chains. This dimer is
conserved, and pairwise structural superpositions yielded
r.m.s.d. values of o1.3 Å (for 275 equivalent Ca pairs;
Supplementary Tables S3 and S4). The interaction is twofold
symmetric; strands b3 and b7 of the ‘subunits’ abut face-to-face at
the core of the dimer (Fig. 1c and 2a). The b1–b2 hairpin forms a
second interface by reaching out to embrace helix aA and the b3–
b4 loop in the opposing subunit (Fig. 2b). Intriguingly, these
structural features interact in a parallel (cis) fashion consistent
with ZNRF3 associating as a dimer on the cell surface.
Structure of a signalling-competent fragment of Rspo2. In the
crystal structure of the isolated RspoFu1–Fu2 protein (Table 1) the
two Fu domains arrange sequentially to form a ladder-like
structure of b-hairpins (Fig. 1d). Each Fu domain comprises three
b-hairpins rigidiﬁed by four disulphide bridges (Fig. 1e), similar
to the cysteine-rich regions found in members of the epidermal
growth factor receptor family (Supplementary Fig. S3b).
The connection between the Fu domains shows considerable
rotational freedom, allowing a 50–60 variation in the relative
interdomain orientation (Supplementary Fig. S4). The N terminal
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of the two domains, Fu1, is distinguished by the extension of the
second b-hairpin (Fig. 1d,e). This prominent loop presents a
solvent exposed methionine (M68) at its tip, which we term the
‘Met-ﬁnger’.
Structure of liganded complexes of ZNRF3ecto and RNF43ecto.
The crystal structures of the ZNRF3ecto–Rspo2Fu1–Fu2 and
RNF43ecto–Rspo2Fu1–Fu2 complexes (Table 1 and Supplementary
Table S1) revealed a 1:1 interaction between Fu1 of the Rspo2Fu1–
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Figure 1 | Unliganded and complexed structures of ZNRF3 and Rspo proteins. (a) Schematic domain organization of Rspo (top) and ZNRF3/RNF43
proteins (bottom) roughly at scale. The domains included in the crystallization constructs are coloured in blue, red and orange. Disulphides are derived
from the crystal structure, except for those of the TSR domain of Rspo, which are based on a model48. (b) Cartoon representation of the fold of the
ZNRF3 ectodomain protomer. b-strands are numbered and a-helices are labelled in alphabetical order from the N to C terminus. (c) Structure of the
recurring ZNRF3ecto dimer with view parallel to the putative membrane layer and from top towards the membrane. An acidic region with sequence
105NNNDEEDLYEY115 is highlighted in red in b and c. (d) The xRspo2Fu1–Fu2 structure. Both b-hairpins and disulphide bridges line up to form a ladder-like
structure. The second b-hairpin of Fu1 contains an exposed methionine side chain. (e) Fu1 and Fu2 share the same architecture, except that the second
b-hairpin of Fu1 is considerably longer. (f) The ZNRF3ecto–Rspo2Fu1–Fu2 complex as the same 2:2 symmetric complex in all seven crystallographic
observations. Shown are two views parallel to the putative membrane orientation. The RNF43ecto–Rspo2Fu1–Fu2 complex resembles one half of this complex
(Supplementary Fig. S5). (g) The ZNRF3ecto–Rspo2Fu1–Fu2 interface. xZNRF3ecto is shown in semi-transparent surface (orange) and ribbon, xRspo2Fu1–Fu2, is
depicted in blue. Residue side chains involved in the interface are shown as sticks and labelled (atom colouring: dark blue, nitrogen; red, oxygen; yellow,
sulphur). Dotted lines represent hydrogen bonds. A corresponding stereo ﬁgure with ﬁnal electron density can be found in Supplementary Fig. S6.
(h) The Met-ﬁnger pocket. Structural features are represented as in g. BR, basic region; PAD, protease-associated domain; SP, signal peptide; TM,
transmembrane; TSR, thrombospondin-related domain.
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Fu2 and a single ZNRF3ecto or RNF43ecto chain (Fig. 1f). As will be
discussed below, all complex structures, except for the RNF43
complex, reveal a conserved 2:2 stoichiometry (Supplementary
Fig. S5a). The interaction interface between Rspo2Fu1–Fu2 and its
two receptors RNF43 and ZNRF3 is essentially the same
(Supplementary Fig. S5b). It involves an interface area of
990±105Å2 (Fig. 1g,h, Fig. 3, Supplementary Fig. S6 and
Supplementary Table S2). Because of the availability of higher
resolution data and multiplicity of data sets, we will ﬁrst focus on
the Rspo2–ZNRF3 interaction. Neither the Rspo2Fu1–Fu2 nor the
ZNRF3ecto dimer show major conformational changes on com-
plex formation (Supplementary Fig. S5). The ﬁrst, extensive, area
of interaction involves hydrophobic interactions interspersed with
hydrophilic (complementarily charged) patches contributed by
the ﬁrst two b-hairpins of the Rspo Fu1 and the region imme-
diately carboxy-terminal to the b3 strand of ZNRF3ecto (Fig. 1g).
The Met-ﬁnger at the tip of the second b-hairpin of Fu1 nestles
into a pocket formed between the b3 strand and the aC–b7 loop
of the ZNRF3ecto, which is lined with hydrophobic residues (I95,
I191, V192, A198; Fig. 1h). The aC–b7 loop is a ﬂexible region in
the unliganded ZNRF3ecto crystal structures and moulds to
interface the RspoFu1–Fu2 M68 in the complex. Overall, the
ZNRF3ecto dimer structure appears less ﬂexible in the complex
structures compared with the unliganded structures. The acidic
region of the b3–b4 loop (immediately adjacent to C104 of the
disulphide bridge) becomes more ordered in the ligand-bound
ZNRF3ecto structures (Supplementary Fig. S2), probably as a
result of electrostatic interactions with a positively charged patch
on Rspo Fu1 (Fig. 3a).
Biophysical and cellular analyses support the structure data.
Analytical ultracentrifugation results are consistent with
ZNRF3ecto dimer formation and analyses of several ZNRF3-
Rspo2 and RNF43-Rspo2 interface mutants (Figs 1g,h and 3)
using surface plasmon resonance (SPR)-binding assays conﬁrm
the crystallographically determined complex structures
(Fig. 4). The single-domain protein mRspo2Fu1 still bound
mZNRF3ecto with high afﬁnity, whereas no detectable binding
was measured for mRspo2Fu2 (Fig. 4b). Consistent with the high
level of surface residue conservation at the interface (Fig. 3a),
the Fu1–Fu2 repeats for all four members of the Rspo family
showed binding to ZNRF3ecto in SPR assays (Fig. 4b). However,
the ﬁne-grained differences in the interface-forming residues did
impact on the binding afﬁnities; the stronger binding of
Rspo2Fu1–Fu2 versus Rspo1Fu1–Fu2 and Rspo4Fu1–Fu2 appeared to
be conferred, in part, by the substitution of isoleucine for
methionine at the tip of the second b-hairpin (Fig. 4c). Previously
reported genetic and cancer-associated mutations further corro-
borate the functional signiﬁcance of the ZNRF3ecto–Rspo2Fu1–Fu2
interface as the generic interaction mode for Rspo1–4 and
ZNRF3/RNF43 (Fig. 4d–g). For example, in Rspo4, the equivalent
of the R65W, Q70R and G72R mutations have been reported in
inherited anonychia8–10. From an analysis of the interaction
interface, it is obvious that these mutations are not compatible
with ZNRF3/RNF43 binding (Fig. 1g). Functional assays that
measure Rspo signalling activity in cells further support the
signiﬁcance of the Rspo–ZNRF3 interface (Fig. 5 and
Supplementary Fig. S7). For example, a Met-ﬁnger mutation,
M68E, which profoundly compromised Rspo–ZNRF3 interaction
in SPR assays, exhibited much weaker signalling activity,
whereas a conserved substitution, M68I, showed slightly
reduced binding to ZNRF3 and relatively normal (or slightly
reduced) signalling capacity (Fig. 5d). Other interface mutants in
Fu1, including the anonychia-associated mutations R65W, Q70R
and G72R, as well as N50R, each exhibited weakened signalling
Table 1 | Data collection and reﬁnement statistics.
ZNRF3ecto/RNF43ecto zZNRF3 mZNRF3 xZNRF3 — — mZNRF3 mZNRF3 xZNRF3 xRNF43
RspoFu1–Fu2 — — — xRSPO2 xRSPO2–Pt mRSPO2 xRSPO2 xRSPO2 xRSPO2
Data collection
Space group P21 P21 P21 P41212 P41212 P212121 P1 P21 C2
Cell dimensions
a, b, c (Å) 36.0, 53.3,
72.5
47.3, 57.8,
50.5
49.2, 58.7,
52.7
97.1, 97.1,
292.9
96.6, 96.6,
290.1
59.8, 77.2,
130.6
36.4, 71.0,
72.0
56.0, 81.2,
71.6
88.9, 35.8,
87.9
a, b, g () 90, 102.1, 90 90, 97.6, 90 90, 93.6, 90 90, 90, 90 90, 90, 90 90, 90, 90 109.2, 101.7,
101.3
90, 113.0, 90 90, 114.6, 90
Resolution (Å)* 42.59–1.60
(1.63–1.60)
37.84–2.00
(2.05–2.00)
37.66–2.40
(2.49–2.40)
39.69–2.20
(2.25–2.20)
39.46–3.20
(3.46–3.20)
66.46–2.80
(2.97–2.80)
38.89–2.40
(2.49–2.40)
65.94–2.10
(2.16–2.10)
32.76–2.70
(2.83–2.70)
Rmerge 0.074 (0.359) 0.089 (0.353) 0.067 (0.478) 0.106 (0.852) 0.218 (1.443) 0.116 (1.345) 0.073 (0.605) 0.115 (0.788) 0.147 (0.550)
I/sI 16.1 (2.3) 9.7 (1.9) 8.7 (1.8) 10.3 (2.0) 23.2 (2.5) 16.0 (2.3) 15.0 (2.6) 17.1 (2.6) 9.5 (2.2)
Completeness (%) 99.8 (99.0) 91.8 (78.6) 99.2 (99.3) 99.1 (99.9) 99.9 (99.9) 99.9 (100) 78.5 (29.2) 93.7 (56.5) 95.8 (97.8)
Redundancy 11.0 (10.9) 3.6 (2.4) 3.0 (3.1) 6.8 (6.6) 50.6 (15.1) 14.4 (14.6) 6.6 (5.8) 17.0 (7.8) 3.8 (3.0)
Reﬁnement
Resolution (Å)* 42.59–1.60
(1.63–1.60)
37.84–2.00
(2.05–2.00)
37.66–2.40
(2.49–2.40)
39.69–2.20
(2.25–2.20)
66.46–2.80
(2.97–2.80)
38.89–2.40
(2.49–2.40)
65.94–2.10
(2.16–2.10)
32.76–2.70
(2.83–2.70)
No. of reﬂections 34,163 15,439 12,423 67,674 14,706 18,529 31,015 6,517
Rwork/Rfree 0.222/0.258 0.200/0.276 0.224/0.299 0.223/0.270 0.236/0.323 0.195/0.273 0.188/0.246 0.317/0.395
No. of atoms
Protein 2,121 2,327 2,220 6,807 3,967 3,815 4,145 1,679
Water 79 29 9 292 — — 220 —
Ligands — — — — 1 — — —
B-factors (Å2)
Protein 41.5 48.6 64.7 47.9 86.2 79.8 35.4 60.4
Water 37.8 42.7 51.0 40.6 — — 36.8 —
Ligands — — — — 79.1 — — —
r.m.s.d.
Bond lengths (Å) 0.008 0.013 0.012 0.012 0.013 0.015 0.013 0.004
Bond angles () 1.199 1.591 1.631 1.418 1.656 1.864 1.604 0.748
Number of monomers or
1:1 complexes
2 3 2 8 2 2 2 1
Dimeric architecture No Yes Yes — Yes Yes Yes No
Protein Data Bank code 4C84 4C86 4C8T 4C8V 4C99 4C9A 4C9R 4C9V
*Highest resolution shell is shown in parenthesis. Statistics of additional structures can be found in Supplementary Table S1.
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Figure 2 | Dimerization interface of xZNRF3ecto. (a) View along the twofold axis away from the putative membrane. (b) xZNRF3ecto–xRspoFu1–Fu2 complex
with close-up view onto the b1–b2 hairpin arm (‘clamp’) embracing the respective other protomer. This interface is stabilized by binding of Rspo
to ZNRF3 and subsequent structuring of the acidic region of the b3–b4 loop drawn in red. Residue numbers refer to mouse proteins.
R65W
S53R
G72R
N50R H86R(43) K108N(43)
RspoFu1–Fu2
RSPOFu1–Fu2 180°
ZNRF3ecto
ZNRF3ecto
S85F(43),
M101T(3)
E112K(3)
H86R(43)
C119R(43)
P118T(43)
D132N(3)
A146G(43) K108N(43)
D140H(43)
A169T(43)
G166C(43)
N167I(43)
A78T(43)
I48T(43)
M173T(43)
L82S(43)
H183R(43)
M83T(43) H86R(43)
P154S,L(43) R127P/Q(43)
P118T(43)
C119R(43)
W120L(3)
M83T(43)
3–4 acidic region
M68I/A/E
L63F
E109K(3) M98T(3)
Q97E(3)
L82S(43)
D102N(4)
G131C(2)
E127V(2), T121I(4)
P134Q(2)
P123L(4)
K113T(1)
G82E(1), G76A(4)
Y82H(2)
L63F(2)
R64Q(2)
D68N(1)
N67K(1)
R69C(2)
G72S(4), G72R(4*)
G52S(1), G51R/V(2)
180°
D50H(3)
E44D(4)
S45P(2)
S53R(2)
Q57H(2)
R87M(4)
R86Q(2)
G84E(2)
F105L(2)
D102N(4)
G67W/E(2)
Q71P(1),
F62S(2)
Q70H(2), Q65R(4*)
R65T(3), R60W(4*)
F105L(2)
G84E(2)
R86Q(2)
R87M(4)
Q57H(2)
S53R(2)
S45P(2)
E44D(4)
D50H(3)
a b
Figure 3 | Characteristics of the ZNRF3 dimer and Rspo–ZNRF3 complex interfaces. (a) An open book view of the ZNRF3–Rspo interface. The surface
contributing to the interface is coloured green on ZNRF3ecto and RspoFu1–Fu2; within this, surface mutants tested in this study are highlighted in red (top).
Rspo and ZNRF3ecto coloured by electrostatic surface potential from red (acidic) to blue (basic) (middle). Sequence conservation across species
coloured from white (not conserved) to black (conserved). (b) Disease-related mutations are plotted onto the molecular surface of Rspo (top) and ZNRF3/
RNF43 (bottom), and are concentrated at the Rspo–ZNRF3/RNF43 interaction interface. Tumour-associated missense mutations derived from the cosmic
database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) are shown in red and missense mutations causal for congenital anonychia on
RSPO4 are shown in orange. Sites in orange on ZNRF3 are mutations of RNF43 that map to the dimer interface of ZNRF3. Numbers 1–4 in parentheses
indicate mutations found in RSPO1 to RSPO4 (top). Number 3 and 43 in parentheses indicate mutations found in ZNRF3 and RNF43, respectively (bottom).
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ability that correlated with reduction in binding to ZNRF3
(Fig. 5e).
Dimerization propensity of ZNRF3 versus monomeric RNF43.
For all ZNRF3ecto–Rspo2Fu1–Fu2 complex structures we deter-
mined (from ﬁve different combinations of species and crystal
forms), the dimer found in most of the unliganded ZNRF3ecto
crystal structures reoccurs (Fig. 1f, Supplementary Fig. S5 and
Supplementary Table S2). The overall assembly thus comprises a
2:2 complex of ZNRF3ecto–Rspo2Fu1–Fu2. The 2:2 complex
resembles a crab with the ZNRF3ecto dimer forming the body
from which the two Rspo2Fu1–Fu2 ligands diverge, without
80a
60
40
c 
(s)
20
0
1.0 1.5
ZN
R
F3
e
ct
o
M
on
om
er
ZN
R
F3
e
ct
o-
R
SP
O
2 F
u1
–F
u2
1:
1 
co
m
pl
ex
ZN
R
F3
e
ct
o-
R
SP
O
2 F
u1
–F
u2
2:
2 
co
m
pl
ex
ZN
R
F3
e
ct
o
di
m
er
2.52.0 3.0
s (S)
3.5 4.0 4.5 5.0
120 h1 6.8 μM
m2 25 nM
h3 60 nM
m4 300 μM
m2Fu1 510 nM
m2Fu2 no
response
100
80
60
N
or
m
al
iz
ed
 re
sp
on
se
40
20
0
[mZNRF3ecto] (M)
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
mZNRF3ecto
mZNRF3ecto E92N, E94T
mZNRF3ecto S90C
xRNF43ecto × xRSPO2Fu1–Fu2
xZNRF3ecto × xRSPO2Fu1–Fu2
b
c
wt
M68I 85 nM
M68E 23 μM
wt
R65W 670 nM
Q70R 22 μM
G72R 27 μM
N
or
m
al
iz
ed
 re
sp
on
se
120
100
80
60
40
20
0
[mZNRF3ecto] (M)
mZNRF3ecto hRNF43ecto mZNRF3ecto
[mZNRF3ecto] (M)
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
120
100
80
60
40
20
0
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
[mZNRF3ecto] (M)
120
100
80
60
40
20
0
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
wt
L63F 109 nM
S53R 182 nM
N50R 5.6 μM
N
or
m
al
iz
ed
 re
sp
on
se
120
100
80
60
40
20
0
[mRSPO2Fu1–Fu2] (M)
LGR5
(chip: hLGR5ecto)
ZNRF3
(chip: RSPO variant)
mZNRF3ecto
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
120
100
80
60
40
20
0
[mRSPO2Fu1–Fu2] (M)
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
120
100
80
60
40
20
0
[mRSPO2Fu1–Fu2] (M)
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
wt 290 nM
E109K 680 nM
M98T 1.5 μM
Q97E 5.6 μM
wt 25 nM
K108N 62 nM
L82S 78 nM
H86R no response
wt
E92N,
E94T
S90C 
650 nM
N
or
m
al
iz
ed
 re
sp
on
se
120
100
80
60
40
20
0
[mRSPOFu1–Fu2 variant] (M)
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5
120
100
80
60
40
20
0
[mZNRF3ecto] (M)
mR22 (wt) 14 nM
mR44 (wt) 73 nM
mR24 25 nM
mR42 240 nM
1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3 1e–10 1e–9 1e–8 1e–7 1e–6 1e–5 1e–4 1e–3
[hLGR5ecto, Ir × mRSPO2Fu1–Fu2] (M)
120
100
80
60
40
20
0
mR22 (wt) 25 nM
mR21 71 nM
mR24 162 nM
mR42 3.6 μM
wt
E92N,
E94T
S90C 
3.5 μM
d e
f g h
i j k
 290 nM
35 nM
 850 nM
206 nM
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3787
6 NATURE COMMUNICATIONS | 4:2787 | DOI: 10.1038/ncomms3787 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
interacting with each other, as the pincers. In contrast, our single
structure of RNF43 in complex with Rspo2Fu1–Fu2 displays
no dimeric architecture.
Dimerization of ZNRF3ecto is weak in solution and the protein
did not behave as a dimer in gel ﬁltration. Still, a propensity
of ZNRF3ecto to dimerize was evident from analytical ultra-
centrifugation data. Broad peaks of ZNRF3ecto from ultraviolet
absorbance data were highly indicative of a rapid equilibrium
of self-association. In sedimentation velocity plots using the faster
interference optics traces of a dimer could be detected (Fig. 4a).
This rapid dimerization was not observed when a glycosylation
site E92N, E94T was engineered into the dimerization interface
observed in the crystal structures. Formation of the observed
crystallographic ZNRF3 dimer in solution is further supported by
the observation of almost quantitative spontaneous crosslinking
of the S90C variant of mZNRF3ecto that introduces a cysteine
close to the dimer symmetry axis (Supplementary Fig. S8).
A crystal structure of this variant at 2.1 Å shows that this
mutation and crosslinking is easily accommodated, requiring
only minor backbone distortions (Supplementary Table S1 and
Supplementary Fig. S8d).
Formation of the ZNRF3ecto–Rspo2Fu1–Fu2 complex also leads
to increased dimerization in solution (Fig. 4a). An explanation for
this is found by careful analysis of the crystal structures. As
outlined before, ligand binding leads to a structuring of the acidic
region of the b3–b4 loop (red in Figs 1b,c and 2b). This same
region of the b3–b4 loop also interacts with the b1–b2 hairpin in
the opposing subunit of the ZNRF3ecto dimer (Fig. 2b). Notably,
the b1–b2 hairpin shows less conformational variation in the
liganded ZNRF3ecto dimer structures, always maintaining a tight
embrace (Supplementary Figs S2b and S5a), consistent with the
Rspo2Fu1–Fu2 interactions contributing an indirect stabilizing
effect on the dimer via the b3–b4 loop. This stabilizing effect
provides an explanation for our results showing that Rspo2Fu1–Fu2
bound weaker to monomerized mZNRF3ecto E92N, E94T but
stronger to predimerized mZNRF3ecto S90C than to the wt
mZNRF3ecto (Fig. 4h).
No dimer is observed in solution for RNF43ecto, even after
binding to mRspo2Fu1–Fu2 (Fig. 4a), and we also see only a minor
propensity for spontaneous cysteine crosslinking of the P77C
(corresponding to S90C of mZNRF3ecto) variant of hRNF43ecto
(Supplementary Fig. S8b). We note that the residues involved in
the dimerization interface of ZNRF3, albeit conserved within the
ZNRF3 family, are not conserved between ZNRF3 and RNF43
(Supplementary Fig. S5c). Furthermore, two glycosylation sites
exist in RNF43 and map to the acidic region of the b3–b4 loop
and the b1–b2 clamp (Supplementary Figs S2 and S5). These sites
are not resolved in the RNF43 complex but might sterically
hamper dimerization.
Rspo interacts with LGRs via Fu2. Fu2, similar to Fu1, is
essential for Rspo signalling function1 (Supplementary Fig. S1).
We therefore suspected that Fu2 might be involved in binding
to other components of the Rspo receptor complex, such as
LGR4/5/6. Indeed, although Rspo1, Rspo1Fu1–Fu2 and Rspo1DFu2
were each co-immunoprecipitated with RNF43, conﬁrming that
Fu1 is critical for binding to ZNRF3/RNF43, Rspo1, Rspo1Fu1–Fu2
and Rspo1DFu1 each immunoprecipitated LGR4, indicating that
Fu2 is the primary binding site for LGR receptors (Fig. 6a,b).
Consistent with these co-immunoprecipitation data, Rspo2Fu1–Fu2
simultaneously bound to ZNRF3 and LGR5 in SPR binding
assays (Fig. 6c–e) with the monomerized ZNRF3ecto binding
weaker and the dimerized S90C variant binding stronger to a
preformed LGR5ecto–RspoFu1–Fu2 complex (Fig. 4k). Our data
therefore support the model of a ZNRF3/RNF43–Rspo–LGR4/5/6
complex assembled through ZNRF3/RNF43–RspoFu1 and
RspoFu2–LGR4/5/6 interactions (Fig. 7).
Rspo–ZNRF3/RNF43 interaction determines signalling
potency. Although there is a clear requirement for both Furin
domains in Rspo ternary complex formation and functional
activation of the Wnt pathway, our results point to the ability of
RspoFu1 to recruit ZNRF3/RNF43 as the major determinant of
activity (for example, Figs 4b and 5b). In biophysical assays, wild-
type mRspo2 and -4 proteins, as well as their Fu1/Fu2 chimeras,
bound with nanomolar afﬁnity to hLGR5ecto (Fig. 4i), further
suggesting that engagement of LGR is not the efﬁciency-deter-
mining step. Cellular assays using Rspo2 Fu1/Fu2 chimeras
showed that a Fu1 repeat from a ‘strong’ Rspo (that is, Rspo2
or -3) was sufﬁcient to induce a higher Wnt response (Fig. 5c).
On the other hand, in spite of an 80-fold (300 mM 43.6 mM)
increase in binding efﬁciency to ZNRF3ecto, replacement of Fu2 of
Rspo4 by that of a ‘strong’ Rspo was not able to enhance Wnt
signalling when expressed at comparable levels (Fig. 5c). Hence, it
can be concluded that functional efﬁciency of the four Rspo
ligands is largely based on their ability to recruit ZNRF3 or
RNF43 via Fu1 into a complex with LGRs.
Discussion
In combination, the structural, biophysical and cell-based studies
we report here for the ZNRF3/RNF43–Rspo system reveal two
modes of interaction: receptor–ligand and receptor dimer. For the
ligand–receptor mode, our data deﬁne a generic architecture for
the interaction between the Rspo ligands, and the ZNRF3 and
RNF43 transmembrane E3 ubiquitin ligases that is conserved
across evolution from ﬁsh to human. Indeed, the differences in
binding afﬁnities, from highest afﬁnity for Rspo2 to lowest for
Rspo4, appear to mirror the trend in biological activity of the four
Rspo proteins (reviewed in ref. 3). Our results highlight the role of
the Fu1 domain of the Rspo protein in ZNRF3/RNF43 binding.
Both Fu domains together have been implicated in Rspo
signalling. The primary role of Fu1 in ZNRF3/RNF43 binding
leaves a substantial surface available for the Rspo to mediate
Figure 4 | Biophysical characterization of the ZNRF3ecto dimer and interface mutants. (a) Sedimentation velocity experiments. A plot of c(s)
(in arbitrary units) against s (in svedbergs). Shown in each case are individual data points and the ﬁt of an appropriate number of Gaussian distributions.
All samples were adjusted to a concentration of 350mM. Also shown arrowed are the expected sedimentation coefﬁcients for the different complexes
observed in the crystal structures as predicted using HYDROPRO (see Methods). (b–h) SPR experiments using mZNRF3ecto (b–e) or mRspo2Fu1–Fu2 (f–h)
as analyte and interface mutants/variants as immobilized ligands. (b) mZNRF3ecto binds to mRspo2Fu1–Fu2 (I39-G144) and retains high afﬁnity to Fu1
(I39-R95) but not to Fu2 (A94-G144). Fu1–Fu2 polypeptides of human or mouse homologues (hRspo1: I32-S143, hRspo3: R32-H147, mRspo4: T29-Q136)
bind with different afﬁnity to mZNRF3ecto. (c) Mutations of the Met-ﬁnger impact afﬁnity. (d) Anonychia mutations of RSPO4 introduced to mRspo2Fu1–Fu2
drastically impair binding. (e) Three additional interface mutants of which two (L63F and S53R) have been found in tumour tissues. (f) As the immobilized
ligand mZNRF3 binds with lower afﬁnity to the mRspo2Fu1–Fu2 analyte. Of the three interface mutants, two (E109K and M98T) have been identiﬁed in
tumour tissues. (g) Three interface mutants of hRNF3ecto have been identiﬁed in tumours, one of which completely disrupts binding. (h) Binding of
mRspo2Fu1–Fu2 to ZNRF3ecto dimer interface mutants. (i) Binding of mRspo2Fu1–Fu2, mRspo4Fu1–Fu2 and chimeras to hLGR5ecto. Single dilution series.
(j) Binding of RspoFu1–Fu2 chimeras to ZNRF3ecto. (k) Binding of the preformed hLGR5ecto,lr–Rspo2Fu1–Fu2 complex to ZNRF3ecto dimer interface mutants.
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formation of a three component complex involving ZNRF3/
RNF43, Rspo and LGR4/5/6 as postulated16. Indeed, our co-
immunoprecipitation results focus LGR4/5/6-binding activity
onto Fu2, consistent with Rspo proteins acting as complex
assemblers (Fig. 7). Whilst we were preparing our paper for
publication, several crystal structures of Rspo1Fu1–Fu2 in complex
with LGR4/5ecto and a single Rspo1Fu1–Fu2–LGR5ecto–RNF43ecto
complex were reported25–28, which fully support this notion.
Unexpectedly, our analyses reveal a dimerization mode for
ZNRF3ecto. The conservation of ZNRF3 ectodomain dimerization
across evolution from ﬁsh to mammals suggests that this
interaction has some role in the mechanism of action of ZNRF3.
It is also noteworthy that three cancer-associated mutations
reported for RNF43 map to the corresponding dimer interface
observed in the ZNRF3ecto crystal structures (Fig. 3b), suggesting
the characteristics of this surface have functional relevance in
RNF43 as well. Many members of the E3 RING ubiquitin ligase
superfamily have been reported to require dimerization for
function (reviewed in ref. 29), a conclusion supported by recent
insights into the mechanism of action of the RING ligase RNF4
(ref. 30). In ZNRF3, the ectodomain may, alongside cytoplasmic
regions, contribute to functionally essential RING domain
dimerization. However, neither our biophysical measurements
nor our structural data for an RNF43 ectodomain in complex
with Rspo2 provide any evidence of a similar dimerization mode
for RNF43; a ﬁnding that argues against ectodomain dimerization
having a central role in ligase activity. The newly reported
structure of the 1:1:1 complex of Rspo1–LGR5–RNF43 also
reveals no RNF43 dimer25. Intriguingly at the level of a simple
modelling exercise, the ternary complex architecture appears
compatible with ZNRF3 dimerization (Fig. 7). All of the currently
available structures are compatible with a dimeric ZNRF3 as
50
40
30
20
10
0
50
60
a b
40
30
20
10
0 S
up
er
To
pF
la
sh
 (R
LU
)
50
d
40
30
20
10
0
50
40
30
20
10
0
50
40
30
20
10
0
Su
pe
rT
op
Fl
as
h 
(R
LU
)
Su
pe
rT
op
Fl
as
h 
(R
LU
)
50
60
c
e
g h
f
40
30
20
10
0
Con
Con
19 kDa CM
IB : His
15 kDa
15 kDa
CM
IB : His
Lysate Lysate
IB : His IB : His
Co
n
Fu
1
Fu
2
hR
1
hR
3
m
R
2
m
R
4
2/
1
2/
3
2/
4
4/
2
Co
n
m
R
2 
w
t
N
50
R
S5
3R
L6
3F
M
68
E
M
68
I
R
65
W
Q7
0R
G
72
R
m
R
2 
w
t
15 kDa
6 kDa
19 kDa
15 kDa
6 kDa
2/1 2/2
(mR2 wt)
2/3 2/4 4/2
Su
pe
rT
op
Fl
as
h 
(R
LU
)
Su
pe
rT
op
Fl
as
h 
(R
LU
)
Su
pe
rT
op
Fl
as
h 
(R
LU
)
Con Con
Con mR2 wt
mR2 wt R65W Q70R G72R Con mR2 wt N50R S53R L63F
M68E M68I
hR1 hR3mR2 mR4mR2 Fu1 Fu2
Figure 5 | Activation of the Wnt pathway assayed by the SuperTopFlash reporter. (a–f) Co-transfected decreasing doses (25, 5 and 1 ng) of His-tagged
R-spondin constructs used for SPR experiments in Fig. 4. Error bars represent s.d. from three replicates. (g,h) Western blots showing expression
levels of the His-tagged R-spondin constructs from whole-cell lysate and conditioned media (CM). Expression for mRspo2 Fu1-His was poor and below the
level of detection; however, the individual Fu1 domain from RSPO1 was detected by western blotting and produced identical results (Supplementary
Fig. S1b,c). RLU, relative luciferase units.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3787
8 NATURE COMMUNICATIONS | 4:2787 | DOI: 10.1038/ncomms3787 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
reported here. However, we note that none of the reported
crystallographic LGR4/5ecto dimers would be compatible with
simultaneous binding of Rspo proteins to both LGR4/5/6
and ZNRF3/RNF43. Our observation is suggestive of Rspo
functioning to sequester ZNRF3 dimers into a complex with
LGR4/5/6. Thus, we may speculate that the difference in
oligomeric state of the ZNRF3 and RNF43 ectodomains points
to some yet to be ascertained difference in their function or
regulation. We note that sequence conservation of the
ectodomain within the ZNRF3 subfamily is far greater than
that within the RNF43 subfamily (Supplementary Table S5),
supporting the notion that for ZNRF3 function or regulation
additional features such as ligand-induced dimerization may be
important.
ZNFR3 and RNF43, alongside the Rspo proteins, have emerged
as a system with signiﬁcant therapeutic potential for a number of
pathological processes. The insights into molecular mechanism
presented here open up new avenues to explore for possible
manipulation of this system.
Methods
Large-scale expression of ZNRF3ecto and RSPOFu1–Fu2. Synthetic com-
plementary DNA clones for ectodomains of mouse and zebraﬁsh ZNRF3 and
Xenopus RNF43 were obtained from Invitrogen/Geneart (Germany). All other
template cDNAs were from the I.M.A.G.E. library.
Xenopus, mouse and zebraﬁsh ZNRF3 ectodomains (residues E25-D191,
K53-L205 and K30-R181, respectively), Xenopus RNF43 ectodomain (T28-D192),
as well as Xenopus and mouse Rspo2Fu1–Fu2 constructs (residues G35-D143, N37 or
I39-G144) were cloned into the pHLsec vector31 that encodes for a C-terminal
His6-tag (His10-tag for mRSPO2Fu1–Fu2). Proteins were expressed separately or
after co-transfection in HEK293T cells seeded into roller bottles. For preparation of
seleno methionine (SeMet)-labelled xRSPO2Fu1–Fu2, the cells were washed 24 h
after transfection with PBS (2 35ml per roller bottle) and the medium was
changed to methionine-free DMEM complemented with 2% dialysed fetal bovine
serum and 40 mgml 1 SeMet. After 4–8 days expression, the medium was
collected and cleared by centrifugation and ﬁltration. The buffer was exchanged to
10mM Tris/HCl, pH 8.0, 500mM NaCl using hollow-ﬁbre ultraﬁltration. Proteins
were puriﬁed using Ni2þ -charged 5ml HisTrap FF columns from GE. Before
sample loading, 25mM imidazole was added to suppress unspeciﬁc binding. The
elution buffer contained 1M imidazole in binding buffer. Individual proteins were
subjected to gel ﬁltration on S200 16/60 pg columns (GE Healthcare) equilibrated
with 10mM HEPES/NaOH, pH 7.5, 150mM NaCl. ZNRF3ecto–RSPO2Fu1–Fu2
complexes were obtained by coexpression or by mixing of equimolar amounts
followed by gel ﬁltration. Because of solubility issues of the complexes, the NaCl
concentration of the gel ﬁltration buffer was increased to 250mM.
Crystallization and data collection. Concentrated proteins were subjected to
sitting drop vapour diffusion crystallization trials employing a Cartesian Tech-
nologies pipetting robot, and usually consisted of 100–300 nl protein solution and
100 nl reservoir solution32. Crystal form I of apo xRSPO2Fu1–Fu2 appeared in
100mM Bis-Tris/HCl, pH 6.3, 200mM ammonium sulphate (AS) and 1.2M
tartrate, pH 7.5, at a protein concentration of 37.5mgml 1. Crystals of form II
appeared in 100mM cacodylate and 1M sodium citrate, ﬁnal pH 7, at a protein
concentration of 24mgml 1. zZNRF3ecto crystallized in 20% (w/v) PEG3350,
200mM CaCl2 (form I) or 25% (w/v) PEG3350, 100mM Bis-Tris, pH 5.5 (form II).
Crystals of mZNRF3ecto appeared at sample concentrations of 49mgml 1 in 25%
(w/v) PEG3350, 200mM MgCl2 and 100mM Tris, pH 8.5, (form I); 20% (w/v)
PEG3350, 5% (w/v) low-molecular-weight polyglutamic acid and 100mM Tris, pH
7.8, (form II); 20% (w/v) PEG8000, 200mMMgCl2 and 100mM Tris, pH 8.5 (form
III); or crystallized alone out of a complex sample with bovine RSPO2Fu1–Fu2 at
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16.2mgml 1 in 0.5M Li2SO4 and 10% (w/v) PEG8000 (form IV). The S90C
variant of mZNRF3ecto crystallized in 45% (v/v) 2-methyl-2,4-pentanediol, 200mM
ammonium acetate and 100mM Bis-Tris, pH 5.5, at a concentration of
38.5mgml 1. Apo xZNRF3ecto crystallized at 25mgml 1 in 20% (w/v) PEG3350,
100mM Bis-Tris propane, pH 6.5, 200mM NaBr (form I), and 20% (w/v)
PEG3350 and 0.200M NaCl (form II). Crystals composed of the complex of
mZNRF3ecto and mRSPO2Fu1–Fu2 were obtained at a concentration of 18mgml 1
in 1.8M AS, 100mM Bis-Tris, pH 6.5, 2% (v/v) PEGMME550. Crystals of the
mixed species complexes of mZNRF3ecto and SeMet xRSPO2Fu1–Fu2 appeared in
25% (w/v) PEG4000, 200mM NaCl, 100mM HEPES/NaOH, pH 7.5 (form I), and
20% (w/v) PEG3350, 200mM sodium citrate, 100mM Bis-Tris propane, pH 6.5
(form II). xZNRF3ecto–xRSPO2Fu1–Fu2 complexes crystallized in 20% (w/v)
PEG3350, 200mM (NH4)F (form I) and 20% (w/v) PEG6000, 100mM MES, pH
6.0 (form II). The complex of xRNF43ecto and xRSPO2Fu1–Fu2 was crystallized in
condition A1 of the PACT premier screen from Molecular Dimensions. For
cryoprotection, crystals were transferred to mother liquor supplemented with 1.7M
sodium malonate, pH 7 (both apo xRSPO2Fu1–Fu2 crystals), with AS to 3M (mouse/
mouse complex), or with PEG200 to achieve total (PEG, polyethylene
glycol)430% (all other ZNRF3 apo and complex crystals) by incrementally
adjusting the concentration of the cryoprotectant. Crystal were then ﬂash-cooled by
dipping into liquid nitrogen. The xRNF43ecto–xRSPO2Fu1–Fu2 complex crystal was
frozen directly and showed strong ice rings. Diffraction data were collected at
DIAMOND synchrotron light source at the beamlines i02, i03, i04 and i24. Crystal
forms II and III of apo mZNRF3ecto had been soaked with a platinum compound,
but showed only low binding of heavy atoms.
Structure determination. The structure of xRspo2Fu1–Fu2 was solved using highly
redundant single-wavelength anomalous dispersion (SAD) data from a Pt(IV)-
soaked crystal that diffracted to 3.2 Å (Table 1). Ten strong anomalous sites could
be identiﬁed by AUTOSHARP33. Reﬁnement and subsequent density modiﬁcation
with SOLOMON lead to clearly interpretable electron density. A partial model
obtained from BUCCANEER34 was used to solve the high-resolution structure.
The model was improved with iterative rounds of manual building in COOT35 and
reﬁnement in REFMAC5 (ref. 36). The structure of mZNRF3ecto in complex with
SeMet-labelled xRSPO2Fu1–Fu2 was solved from SAD data collected at the Se
K-absorption edge. Albeit only one component of the complex was labelled and the
complex being crystallized in the low-symmetry space group P1, the Se atom
substructure (four sites) could be identiﬁed by PHENIX HYSS37 from average
redundancy data (Supplementary Table S1). An initial model generated by
AUTOSOL was used to solve the high-resolution mZNRF3ecto structure
(Supplementary Table S1). All other structures were solved by molecular
replacement with PHASER38 and completed by manual rebuilding in COOT and
reﬁnement with REFMAC5. Models were validated with MOLPROBITY39.
Superpositions were performed within CCP4 or COOT using the SSM algorithm.
Electrostatics potentials were generated using APBS40, surface sequence
conservation was calculated using CONSURF41 and interface areas of proteins
were calculated using the PISA web server42. Figures were produced in PYMOL
and assembled in PHOTOLINE32.
Analytical ultracentrifugation. xZNRF3ecto–xRSPO2Fu1–Fu2 and xRNF43ecto–
xRSPO2Fu1–Fu2 complexes and apo mZNRF3ecto variants at 350 mM in 10mM
HEPES/NaOH, 250mM NaCl were subjected to sedimentation velocity experi-
ments at 20 C using an Optima Xl-I analytical ultracentrifuge (Beckman) with
3mm or 12mm double sector centerpieces in an An-60 Ti rotor (Beckman) at
40,000 r.p.m. Sedimentation was monitored by ultraviolet absorption at 300 nm
and by Rayleigh interference. Data were analysed using SEDFIT operating in c(s)
and c(s,f/fo) modes (with a frictional coefﬁcient range of 1–2 in the latter case and a
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resolution in s of 100)43. The resulting sedimentation coefﬁcient distributions were
plotted using ProFit (Uetikon am See, CH). The crystal structures were modelled
hydrodynamically using the programme HYDROPRO44.
SPR equilibrium binding studies. Afﬁnity between variants of mZNRF3ecto,
human RNF43ecto and mRSPO2Fu1–Fu2 was measured at 25 C in 10mM HEPES/
NaOH, pH 7.5, 150mM NaCl, 0.005% Tween20 using a Biacore T200 machine (GE
Healthcare). Synthetic DNA corresponding to mZNRF3(K53-L205), hRNF43(Q44-
L188) and mRSPO2(I39-G144), as well as variants thereof, was obtained from
Invitrogen/Geneart (Germany) and cloned into a variant of the pHLsec vector
encoding a C-terminal recognition sequence for the Escherichia coli BirA enzyme.
Biotinylation at this sequence tag was performed as described45. Experiments were
performed as described before46, with the biotinylated variants immobilized to the
chip surface precoupled with approximately 10,000 resonance units (RU) of
streptavidin. Immobilized protein amounts varied between 350 and 1,000 RU
(1 experiment with 1,650 RU). The amount of immobilized protein did not seem to
strongly inﬂuence the binding model. After each injection of analyte, the chip
surface was regenerated with 2M MgCl2, 10mM HEPES/NaOH, pH 7.5 (RSPO
coupled), 100mM phosphate, pH 3.7, 2M NaCl and 1% (v/v) Tween20 (RNF43 or
ZNRF3 coupled) or 25% ethylene glycol, 2M NaCl, 100mM HEPES/NaOH, pH
7.5, 1% Tween20 (LGR coupled) to return to baseline levels. Data were ﬁtted to a
Langmuir adsorption model B¼BmaxC/(KdþC), where B is the amount of bound
analyte and C is the concentration of analyte in the sample. Data were then
normalized to a maximum analyte-binding value of 100. Unless stated otherwise,
data points correspond to average from two independent dilution series.
Co-immunoprecipitation binding assays. Full-length human RSPO1-Myc
(1–263), and domains of Fu1/Fu2 (1–147) and TSR (1–20, 144–263), were
originally reported in ref. 47. On the basis of the disulphide bond pattern resolved
in the crystal structure, new individual Fu domain deletions were generated:
deltaFurin1 (del 39–94; Rspo1DFu1) and deltaFurin2 (del 97–142; Rspo1DFu2). For
immunoprecipitation, conditioned medium from HEK293T cells transfected using
FugeneHD with RSPO1-Myc, Furin1/2-Myc, TSR-Myc, deltaFurin1-Myc or del-
taFurin2-Myc was mixed with conditioned medium from cells transfected with
IgG, Human RNF43 ECD-IgG (1–198) or mouse HA-Lgr4 ECD (from ref. 11), and
incubated at 4 C overnight. The mixture was then incubated with protein
G-agarose beads for 2 h at 4 C and washed with buffer (150mM NaCl, 1mM
EDTA, 2.5mM EGTA, 10% glycerol, 0.1% Tween20 with protease inhibitors).
Protein was eluted using 2 SDS sample buffer and separated by SDS–PAGE.
Western blotting was performed by using horseradish peroxidase-conjugated anti-
human IgG (Calbiochem), anti-HA or anti-c-Myc. For co-immunoprecipitation
assays, anti-Myc (9E10, Santa Cruz) was used at a 1:100 concentration. For western
blots, primary antibodies were diluted 1:1000 and secondary antibodies were
diluted 1:10000 from stocks.
Activity assays. To assess Rspo activation of the Wnt signalling pathway, a
traditional dual-luciferase assay consisting of the Wnt-responsive SuperTopFlash
reporter (normalized to a control promoter driving Renilla luciferase) was used as
previously described46. Mammalian cell transfections were done in HEK293T
(ATCC CRL-11268) cells and performed in triplicate for each sample condition.
Cells were plated at 1 105 per ml in 24-well plates and transfected the following
day with a total of 200 ng of DNA per well (50 ng SuperTopFlash, 10 ng TK-Renilla,
experimental expression vectors and balanced with empty vector). Lysates were
collected 36 h post transfection and used with the Dual-luciferase reporter system
(Promega). Fireﬂy and Renilla luciferase activity was measured using the Wallac
1420 multilabel counter in 96-well plates. Normalized data expressed in relative
luciferase units was averaged from triplicate assays and error bars reﬂect s.d.
Representative results are shown from one of multiple independent experiments.
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